Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 2 Trials for Cefotaxime (DB00493)

DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting2 IdentifierTitlePurposeDrugs
NCT03147612Low-Intensity Chemotherapy and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaTreatment
NCT01424982Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaTreatment
NCT02220985Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDTreatment